Symptoms of Huntington's disease appear late in life. Research reveals how DNA repeats grow toxic over time, explaining the ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

In South Korea, as of 2022, there are only 340 patients with this rare disease. Huntington’s disease takes about 15 to 20 years from diagnosis to death. While it has been known that the ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company"). Atalanta, a biotechnology company based in ...

Huntington's disease kills a population of cells called ... When large numbers of these cells die, patients develop involuntary movements in the arms, legs, and face, and many patients also ...

New genetic research shows why some people develop deadly Huntington's disease earlier than others. The findings could lead to better treatments.

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...